The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran ...

What Is the Current and Future Market Size of the Oxlumo Market? The Oxlumo market has experienced notable expansion in recent years, demonstrating steady growth: .The market size increased from ...

Givlaari is approved for the treatment of acute hepatic porphyria. Oxlumo is approved for treating primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.